Epidermal growth factor receptor mutation and treatment outcome of mediastinoscopic N2 positive non-small cell lung cancer patients treated with neoadjuvant chemoradiotherapy followed by surgery-Reference-Cited by-同舟云学术

Epidermal growth factor receptor mutation and treatment outcome of mediastinoscopic N2 positive non-small cell lung cancer patients treated with neoadjuvant chemoradiotherapy followed by surgery

Published:2013-03 Issue:3 Volume:79 Page:300-306
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Ahn Hee Kyung,Choi Yoon-La,Han Joung Ho,Ahn Yong Chan,Kim Kwhanmien,Kim Jhingook,Shim Young Mog,Um Sang-Won,Kim Hojoong,Kwon O Jung,Sun Jong-Mu,Ahn Jin Seok,Park Keunchil,Ahn Myung-Ju

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference18 articles.

1. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial;Betticher;J Clin Oncol,2003

2. Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study;Betticher;Br J Cancer,2006

3. ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy;Hwang;Cancer,2008

4. Is trimodality approach better then bimodality in stage IIIA N2 positive non-small cell lung cancer?;Park;Lung Cancer,2006

5. Somatic EGFR mutation and gene copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non-small cell lung cancer;Dahabreh;Clin Cancer Res,2010

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The role of miR-128 in cancer development, prevention, drug resistance, and immunotherapy;Frontiers in Oncology;2023-01-19

2. The prognosis of non-small cell lung cancer patients according to endobronchial metastatic lesion;Scientific Reports;2022-08-10

3. Efficacy and Safety of Neoadjuvant Targeted Therapy vs. Neoadjuvant Chemotherapy for Stage IIIA EGFR-Mutant Non-small Cell Lung Cancer: A Systematic Review and Meta-Analysis;Frontiers in Surgery;2021-08-19

4. Integrating immune checkpoint inhibitors and targeted therapies in the treatment of early stage non-small cell lung cancer: a narrative review;Translational Lung Cancer Research;2020-12

5. Epidermal Growth Factor Receptor Mutations in Resectable Non-Small Cell Lung Cancer Patients and their Potential Role in the Immune Landscape;Medical Science Monitor;2019-11-20